Country for PR: United States
Contributor: PR Newswire New York
Monday, May 20 2019 - 14:01
A New Approach to Treating Alzheimer's Disease Receives Major NIA Backing
RESEARCH TRIANGLE PARK, North Carolina, May 20, 2019 /PRNewswire-AsiaNet/ --

- T3D Therapeutics to Receive $9 Million Multiyear National Institute on Aging 
Grant for Phase 2 PIONEER Study in Mild-to-Moderate Alzheimer's Disease Patients

T3D Therapeutics, a clinical stage drug development company engaged in the 
development of T3D-959 (the "Company"), a new orally administered treatment for 
Alzheimer's disease (AD), announced today that it has received a grant expected 
to total $9 million dollars over four years from the National Institute on 
Aging (NIA), part of NIH, to help fund a Phase 2 clinical study of T3D-959, a 
novel, metabolic-focused AD drug treatment. 

The Phase 2 PIONEER study (Prospective therapy to Inhibit and Overcome 
Alzheimer's Disease Neurodegeneration via Brain EnErgetics and Metabolism 
Restoration) is expected to initiate patient dosing in early 2020. PIONEER is a 
double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy 
study expected to enroll up to 252 adults with mild-to-moderate Alzheimer's 
disease (MMSE 16-26). PIONEER will enroll subjects who will receive one of 
three different doses of T3D-959 or a placebo for 24 weeks. 

"We see this grant award as recognition that improving inherent metabolic 
defects in Alzheimer's disease is a vital and largely unexplored therapeutic 
avenue in need of pursuit is a testament to the potential for T3D-959 to treat 
AD, a disease that we view as a chronic anorexia of the brain" said Chief 
Executive Officer John Didsbury, Ph.D. ( ) "We are truly honored by 
the support of the NIA and the confidence that our peers have shown in the 
science underpinning T3D-959."

"Given the enormous and growing impact of Alzheimer's on patients and families, 
there is an urgent need to develop and rigorously evaluate a larger and more 
diversified portfolio of promising late clinical stage treatments," said George 
Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer's. "NIA's support of 
Phase 2 studies - including this study from T3D Therapeutics - is to be 
commended and scaled if we are going to achieve our national goal of 
effectively treating Alzheimer's in the near future."

"NIA/NIH and its peer review system are to be lauded for supporting the logic 
of this new approach and excellent science of the T3D-959 program" said Robert 
Ingram, former Chief Executive Officer and Chairman of Glaxo/Wellcome.

Warren Strittmatter, M.D., Chief Medical Officer of T3D Therapeutics, Emeritus 
Professor of Neurology at Duke University Medical Center and Alzheimer's 
Association Zenith Award winner said, "During my lengthy tenure treating AD 
patients I have seen firsthand the frustrations of caregivers and patients at 
the lack of an effective therapy with the plethora of recent drug development 
failures causing them to lose hope.  This award provides great support for our 
promising new therapy to give them renewed optimism. AD is being increasingly 
recognized as resulting from abnormal brain metabolism.  T3D-959 is targeted 
toward those metabolic pathways which appear to ultimately produce amyloid 
plaques, tau tangles, inflammation and, most importantly, the dementia." 

PIONEER is supported by the NIA under award number R01AG061122.

About T3D Therapeutics, Inc.

T3D Therapeutics, Inc. is a privately-held, Research Triangle Park, NC-based 
company. The Company has an exclusive license to T3D-959, its lead product 
candidate, and a platform of structurally-related molecules. T3D Therapeutics' 
mission is to develop and commercialize T3D-959 for the treatment of 
Alzheimer's disease and Mild Cognitive Impairment. T3D-959 is a small molecule, 
orally-delivered, brain-penetrating PPAR delta/gamma dual nuclear receptor 
agonist designed to improve glucose and lipid metabolism dysfunctions present 
in AD and other neurodegenerative disorders. 

For more information visit

Investor Contact

John Didsbury, Ph.D., CEO
T3D Therapeutics, Inc.
Email: info (at) t3dtherapeutics (dot) com

SOURCE  T3D Therapeutics, Inc.